Your browser is no longer supported. Please, upgrade your browser.
ABBV AbbVie Inc. daily Stock Chart
AbbVie Inc.
IndexS&P 500 P/E23.56 EPS (ttm)4.10 Insider Own0.10% Shs Outstand1.61B Perf Week5.53%
Market Cap155.07B Forward P/E14.72 EPS next Y6.55 Insider Trans-26.80% Shs Float1.59B Perf Month10.38%
Income6.62B PEG1.67 EPS next Q1.38 Inst Own70.80% Short Float1.13% Perf Quarter29.28%
Sales26.71B P/S5.81 EPS this Y16.20% Inst Trans-0.01% Short Ratio2.79 Perf Half Y51.18%
Book/sh3.77 P/B25.59 EPS next Y18.58% ROA10.00% Target Price90.50 Perf Year57.06%
Cash/sh4.48 P/C21.52 EPS next 5Y14.14% ROE119.70% 52W Range55.06 - 96.44 Perf YTD54.07%
Dividend2.56 P/FCF56.70 EPS past 5Y10.90% ROI18.00% 52W High0.04% Beta1.53
Dividend %2.65% Quick Ratio1.30 Sales past 5Y8.00% Gross Margin76.70% 52W Low75.22% ATR1.87
Employees30000 Current Ratio1.40 Sales Q/Q7.60% Oper. Margin36.70% RSI (14)79.34 Volatility2.37% 1.95%
OptionableYes Debt/Eq6.20 EPS Q/Q21.30% Profit Margin24.80% Rel Volume1.45 Prev Close96.04
ShortableYes LT Debt/Eq5.63 EarningsOct 27 BMO Payout58.90% Avg Volume6.46M Price96.48
Recom2.30 SMA207.46% SMA5017.40% SMA20037.31% Volume9,303,656 Change0.46%
Oct-02-17Upgrade Leerink Partners Mkt Perform → Outperform
Sep-25-17Downgrade UBS Buy → Neutral $79 → $92
Aug-17-17Initiated Evercore ISI Outperform $95
Jun-22-17Upgrade Societe Generale Hold → Buy
Mar-22-17Upgrade Societe Generale Sell → Hold
Oct-31-16Downgrade Credit Suisse Outperform → Neutral
Oct-18-16Initiated Leerink Partners Mkt Perform $70
Sep-08-16Downgrade JP Morgan Overweight → Neutral
Sep-02-16Initiated Raymond James Outperform $82
Jun-08-16Downgrade Morgan Stanley Overweight → Equal-Weight
Apr-06-16Initiated Societe Generale Sell $47
Mar-15-16Initiated Deutsche Bank Hold $63
Feb-23-16Upgrade Citigroup Neutral → Buy
Dec-01-15Downgrade Barclays Overweight → Equal Weight $73 → $72
Nov-02-15Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-23-15Reiterated UBS Buy $81 → $78
Sep-28-15Upgrade Citigroup Sell → Neutral
Jul-22-15Initiated Sun Trust Rbsn Humphrey Buy
Jun-17-15Initiated Piper Jaffray Overweight
Jun-08-15Reiterated Jefferies Buy $86 → $90
Oct-19-17 09:19AM  Zacks Market Edge Highlights: Gilead, Biogen, Teva, AbbVie and Aetna Zacks
07:47AM  3 Top Stocks Billionaires Love Motley Fool
06:11AM  2 Great Stocks For Retirees Motley Fool
Oct-18-17 02:20PM  Micron, Abbvie, Sherwin-Williams, Wynn Resorts & Exxon CNBC Videos
01:59PM  Bulls bet on two key Dow stocks. Plus, financials could b... CNBC Videos
08:30AM  AbbVie and Harpoon Therapeutics Announce Immuno-Oncology Research Collaboration PR Newswire
08:06AM  See what the IHS Markit Score report has to say about AbbVie Inc. Markit
08:00AM  AbbVie to Present at the 2017 Credit Suisse Health Care Conference PR Newswire
06:36AM  What's in the Cards for Novartis (NVS) This Earnings Season? Zacks
Oct-17-17 07:33PM  Where to Find Value in Healthcare Stocks Zacks
10:48AM  Sanofi/Regeneron's Dupixent Succeeds in Phase II Study Zacks
10:37AM  J&J (JNJ) Beats on Q3 Earnings, Actelion Buyout Drives Sales Zacks
08:03AM  The Zacks Analyst Blog Highlights: AbbVie, American Express, Abbott, United Technologies and VMWare Zacks
07:10AM  4 things that might surprise investors this earnings season MarketWatch
Oct-16-17 03:34PM  Top Research Reports for AbbVie, American Express & Abbott Zacks
09:38AM  J&J's Psoriasis Drug Stelara Gets FDA Nod for Adolescent Use Zacks
07:39AM  This drug may be able to treat both womens health disorders and prostate cancer MarketWatch
Oct-14-17 10:33AM  Better Buy: AbbVie Inc. vs. Merck Motley Fool
Oct-13-17 11:18AM  Cancer Space Update: Lung & Breast Cancer Studies in Focus Zacks
10:38AM  Trump to scrap a crucial part of Obamacare Yahoo Finance Video
09:45AM  Fundamental Equity Analysis Consolidated Research on Johnson & Johnson, Home Depot, Adobe, Disney, AbbVie, and eBay Developing Opportunities, Future Expectations, and Projections GlobeNewswire
07:02AM  Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy InvestorPlace
06:03AM  Why 2017 Could Be This Stock's Best Year Yet Motley Fool
Oct-12-17 09:45PM  3 Stocks for Baby Boomers to Reach Their Goals Motley Fool
02:35PM  Top 5 Biotech Stocks for 2017 Investopedia
11:24AM  New Law May Pressure Drug Prices
08:48AM  Is the Options Market Predicting a Spike in AbbVie (ABBV) Stock? Zacks
08:00AM  Trending: Oil Rises as Supply Glut Fears Abate ETF Database
Oct-11-17 07:36PM  How Safe Is AbbVie's Dividend? Motley Fool
04:36PM  Is AbbVie the Best Dividend Stock in Healthcare? Motley Fool
03:41PM  AbbVie: You're Upgrading ItNow?
03:34PM  Allergan's Uterine Fibroids Candidate's NDA Accepted by FDA Zacks
02:57PM  AbbVie Demonstrates Leadership in HCV with New MAVYRET (glecaprevir/pibrentasvir) Data to be Presented at The Liver Meeting® 2017 PR Newswire
08:07AM  Biotech Stock Roundup: Amgen's Imlygic Data Promising, Regeneron Scores Win in PCSK9 Lawsuit Zacks
07:30AM  Dividend Coverage: This Pharmaceutical Company has Raised Dividend By 60% since 2013; Will Trade Ex-Dividend on October 12, 2017 ACCESSWIRE
Oct-10-17 01:30PM  Healthcare: Are These the Best Dividend Stocks to Buy Now? Motley Fool
08:00AM  AbbVie and Turnstone Biologics Announce Global Collaboration on Viral Immunotherapies in Oncology PR Newswire
06:04AM  3 Healthcare Dividend Stocks Ideal for Retirees Motley Fool
Oct-09-17 08:00AM  AbbVie to Host Third-Quarter 2017 Earnings Conference Call PR Newswire
Oct-08-17 08:08AM  3 Best Healthcare Dividend Aristocrat Stocks You Can Buy Right Now Motley Fool
08:01AM  AbbVie's Fast Becoming a Top Stock to Buy Now Motley Fool
Oct-07-17 10:43AM  3 Blockbuster Drugs That Still Cost More Than They Should Motley Fool
Oct-06-17 07:00PM  3 Top Stocks Wall Street Insiders Love Motley Fool
04:10PM  Here's What's Has Happened in the HCV Space Lately Zacks
11:38AM  Gilead Sciences & AbbVie: Mother Always Told Me to Share
07:18AM  Everything Is Going Right for AbbVie: Is It the Best Biotech Stock to Buy Right Now? Motley Fool
Oct-05-17 10:54PM  'Nobody's talking about' 2 medical conditions that affect 8 million women in America but that could be about to change Business Insider
06:18PM  Second U.S. jury finds AbbVie misrepresented risks of AndroGel Reuters
05:43PM  AbbVie hit with $140 mln verdict in AndroGel trial -lawyer Reuters
10:32AM  AbbVie (ABBV) Stock Up Almost 17% in One Month: Here's Why Zacks
09:50AM  Top 4 Marijuana Stocks to Watch Investopedia
06:03AM  3 Big Pharma Stocks Set to Succeed Motley Fool
Oct-04-17 08:00AM  The Hepatitis Drug Market Is Worse Than Wall Street Realizes Bloomberg
07:54AM  Biotech Stock Roundup: Endocyte Shoots up on Deal, Amgen-AbbVie Settle Humira Litigation Zacks
Oct-03-17 09:00PM  Why Shares in AbbVie Soared 18% in September Motley Fool
12:20PM  Analysts Act on Health Care Stocks
09:24AM  Will Gilead & AbbVie Benefit from Merck's Decision to Drop Two HCV Programs? Zacks
07:42AM  Quarterly Performance of Eli Lillys New Products Market Realist
06:03AM  Good News and Bad News for Gilead Sciences: Which Carries More Weight? Motley Fool
Oct-02-17 04:02PM  AbbVie Patent Deal Staves Off Amgen Competition, But Others Lurk Investor's Business Daily
12:18PM  Plenty Of Opportunity In AbbVie, Even After Recent Run Benzinga
11:38AM  AbbVie Stock Upgraded: What You Need to Know Motley Fool
10:03AM  AbbVie: Better Late Than Never
08:40AM  Merck Drops Two HCV Combination Programs Amid Competition Zacks
Oct-01-17 05:07PM  Merck Hepatitis C exit could lift the spaces two remaining drugmakers MarketWatch
Sep-30-17 12:33AM  [$$] Merck Abandons New Hepatitis C Drugs Amid Crowded Market The Wall Street Journal
Sep-29-17 03:09PM  AbbVie, Amgen Resolve Humira Patent Dispute
01:23PM  [$$] Merck Abandons New Hepatitis C Drugs The Wall Street Journal
11:55AM  AbbVie's Humira Is an Ageless Wonder Bloomberg
10:44AM  AbbVie and Applied Materials Rose on September 28 Market Realist
07:24AM  Amgens rival to AbbVies Humira to launch in 2023 MarketWatch
06:04AM  How Good Is AbbVie's Humira Deal With Amgen? Motley Fool
12:07AM  AbbVie, Amgen Reach Settlement in Humira Patent Dispute The Wall Street Journal
Sep-28-17 05:44PM  AbbVie, Amgen Reach Humira Settlement The Wall Street Journal
05:01PM  AbbVie Inc. -- Moody's: AbbVie's Humira patent settlement reduces uncertainty Moody's
04:52PM  Why Amgen's Drug Win Sent AbbVie Stock Into The Stratosphere Investor's Business Daily
04:45PM  DexCom and Rite Aid tumble while Abbott and AbbVie rise Associated Press
04:30PM  Why BlackBerry, AbbVie, and bluebird bio Jumped Today Motley Fool
03:55PM  Gilead Sciences: 'We Don't Think That His Departure Is a Red Herring'
12:46PM  AbbVie: Has the Humira Cloud Lifted?
11:00AM  3 High-Yield Stocks With Virtual Monopolies Motley Fool
09:50AM  UPDATED: Under Amgen and AbbVie agreement, rival drug to AbbVie's Humira expected to launch in 2023 MarketWatch
09:10AM  Bristol-Myers Squibbs Opdivo and Recent Developments Market Realist
09:10AM  Gilead (GILD) Gets Approval for HCV Drug Sovaldi in China Zacks
08:00AM  AbbVie Announces Global Resolution of HUMIRA® (adalimumab) Patent Disputes with Amgen PR Newswire
Sep-27-17 03:48PM  Bristol-Myers Squibbs Important Recent Developments Market Realist
12:53AM  AbbVie Announces Approval of MAVIRET (glecaprevir/pibrentasvir) for the Treatment of Chronic Hepatitis C in All Major Genotypes (GT1-6) in Japan PR Newswire
Sep-26-17 01:43PM  Analysts Take Action on Health Care Stocks
12:51PM  Gilead Sciences: New Market, Same Problem?
08:39AM  The Creative Ways Drugmakers Are Delaying Generics Motley Fool
08:25AM  Biotech Stock Roundup: Amgen Reiterates 2017 Outlook, Intercept Hit by Ocaliva Safety Issues Zacks
07:17AM  3 Bargain Biotech Stocks You Can Buy Today Motley Fool
Sep-25-17 10:49AM  Abbvie/Bristol-Myers Inks Deal to Develop Therapeutic Cancer Zacks
09:29AM  UBS Downgrades AbbVie; Here's What Changed Analysts' View Benzinga
07:50AM  Corporate News Blog - AbbVie and Bristol-Myers Squibb Pronounce Their Clinical Research Collaboration to Assess a Therapeutic Regimen for Lung Cancer ACCESSWIRE
Sep-24-17 07:00AM  AbbVie's Unfazed by the Risk of Generic Humira Motley Fool
Sep-22-17 03:14PM  Gilead's (GILD) Epclusa Receives Label Expansion in Canada Zacks
07:43AM  3 Big Biotech Stocks to Buy This Fall Motley Fool
07:00AM  AbbVie and Bristol-Myers Squibb Announce Clinical Research Collaboration to Evaluate a Therapeutic Regimen in Advanced Solid Tumors PR Newswire
06:41AM  Ask a Fool! We Answer Your Healthcare Questions on Trials, Patents, and Pharmacy Retailers Motley Fool
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. The company offers HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; IMBRUVICA, an oral therapy for the treatment of patients with chronic lymphocytic leukemia; and VIEKIRA PAK, an interferon-free therapy, with or without ribavirin, for the treatment of adults with genotype 1 chronic hepatitis C. It also provides Kaletra, an anti- human immunodeficiency virus(HIV)-1 medicine used with other anti-HIV-1 medications as a treatment that maintains viral suppression in HIV-1 patients; Norvir, a protease inhibitor indicated in combination with other antiretroviral agents to treat HIV-1; and Synagis to prevent RSV infection at-risk infants. In addition, the company offers AndroGel, a testosterone replacement therapy for males diagnosed with symptomatic low testosterone; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid to treat hypothyroidism; and Lupron, a product for the palliative treatment of prostate cancer, endometriosis, and central precocious puberty, as well as for the treatment of patients with anemia. Further, it provides Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Sevoflurane, an anesthesia product for human use; and ZINBRYTA, a subcutaneous treatment for relapsing forms of multiple sclerosis. The company sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. AbbVie Inc. has collaboration agreements with C2N Diagnostics; Calico Life Sciences LLC; Infinity Pharmaceuticals, Inc.; M2Gen; and Principia Biopharma Inc. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Michael Robert A.VP, ControllerSep 28Sale88.006,699589,51210,007Sep 29 05:02 PM
SALEKI-GERHARDT AZITASVP, OperationsSep 11Option Exercise24.214,800116,19993,099Sep 12 05:40 PM
SALEKI-GERHARDT AZITASVP, OperationsSep 11Sale85.028,300705,65584,799Sep 12 05:40 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 07Option Exercise51.42193,1319,930,796469,623Aug 08 07:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 07Sale71.00193,13113,713,186276,492Aug 08 07:26 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 04Option Exercise51.4222,0381,133,194364,391Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 04Sale71.0722,0381,566,166276,492Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 03Option Exercise51.4265,8613,386,573342,353Aug 04 05:01 PM
GONZALEZ RICHARD AChairman of the Board and CEOAug 03Sale71.0065,8614,676,131298,530Aug 04 05:01 PM
RAPP EDWARD JDirectorJul 31Buy70.454,000281,78215,498Aug 02 05:05 PM
Gosebruch Henry OChief Strategy OfficerJul 31Sale70.0918,0001,261,63883,737Aug 02 05:05 PM
Gosebruch Henry OChief Strategy OfficerJul 31Sale70.4230021,12783,437Aug 02 05:06 PM
Schumacher Laura JExecutive Vice PresidentJun 14Option Exercise29.2379,8002,332,275187,625Jun 15 05:05 PM
ALBAN CARLOSEVP, Commercial OperationsJun 14Option Exercise24.2145,8001,108,736160,545Jun 15 05:05 PM
Schumacher Laura JExecutive Vice PresidentJun 14Sale70.0079,8005,586,000107,825Jun 15 05:05 PM
ALBAN CARLOSEVP, Commercial OperationsJun 14Sale70.0045,8003,206,000114,745Jun 15 05:05 PM
GONZALEZ RICHARD AChairman of the Board and CEOMay 19Sale65.4971,2354,665,063278,727May 23 05:13 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMay 18Option Exercise28.6238,3001,095,994221,843May 19 05:01 PM
CHASE WILLIAM JEVP, Chief Financial OfficerMay 18Sale65.3538,3002,502,905183,543May 19 05:01 PM
ALBAN CARLOSEVP, Commercial OperationsMay 04Sale67.0043,0002,881,000114,745May 08 05:13 PM
AbbVie Inc.10% OwnerMar 28Sale22.50450,00010,125,0001,190,473Mar 30 05:48 PM
Schumacher Laura JExecutive Vice PresidentMar 10Sale65.2640,0002,610,257107,825Mar 10 05:22 PM
Michael Robert A.VP, ControllerMar 10Sale65.295,132335,06816,706Mar 10 05:22 PM
RICHMOND TIMOTHY J.SVP, Human ResourcesMar 10Sale65.2922,4511,465,82626,078Mar 10 05:21 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 08Option Exercise27.9572,0162,012,610422,763Mar 10 05:20 PM
GONZALEZ RICHARD AChairman of the Board and CEOMar 08Sale64.2572,0164,627,028350,747Mar 10 05:20 PM
HURWICH THOMAS A.VP, ControllerFeb 28Sale61.892,311143,03167,276Mar 02 06:12 PM
SALEKI-GERHARDT AZITASVP, OperationsFeb 02Option Exercise27.292,40065,4965,431Feb 03 05:21 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 02Option Exercise27.296,600180,114178,970Dec 02 05:08 PM
CHASE WILLIAM JEVP, Chief Financial OfficerDec 02Sale59.196,600390,654172,370Dec 02 05:08 PM
HURWICH THOMAS A.VP, ControllerNov 16Option Exercise28.863,10089,47564,549Nov 18 05:39 PM
HURWICH THOMAS A.VP, ControllerNov 16Sale62.003,100192,20061,449Nov 18 05:39 PM